I am advised that the National Centre for Pharmacoeconomics periodically conducts and publishes peer-reviewed research in the area of Health Technology Assessment. This research ensures the methods used are robust and are in line with best practice.
The research referred to is not yet published but has been presented at a recent international conference. The research concluded that broadening the economic perspective of the HTA did not alter the final NCPE reimbursement recommendations for Orphan Medicinal Products included in the study.
I am informed by the NCPE that it is happy to share the final abstract with the Deputy once the research has been published.